SPC
ACXP icon

Sigma Planning Corp’s Acurx Pharmaceuticals ACXP Stock Holding History

Sigma Planning Corp’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-500
Closed -$38.3K – 1223
2023
Q4 		$38.3K Buy
+500
New +$37.7K ﹤0.01% 832

Other funds holding ACXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sigma Planning Corp's ACXP Position: Q1 2024 in Review

Sigma Planning Corp sold out of Acurx Pharmaceuticals (ACXP) in Q1 2024, closing a stake of 500 shares — an estimated $38.3K sold.

Sigma Planning Corp first reported a position in ACXP in Q4 2023 and held it in 1 quarter. The position peaked at $38.3K in Q4 2023. 26 funds tracked by Wall St. Rank hold ACXP as of Q1 2024.

  • Sigma Planning Corp reported no remaining Acurx Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Sigma Planning Corp sold 500 Acurx Pharmaceuticals shares in Q1 2024, an estimated $38.3K.
  • Sigma Planning Corp first reported a position in Acurx Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Sigma Planning Corp's Acurx Pharmaceuticals position peaked at $38.3K in Q4 2023.
  • 26 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2024.

Based on Sigma Planning Corp's 13F filing for Q1 2024, filed 2 May 2024.